– TreeFrog will present two posters, one on their cell therapy program in Parkinson’s Disease and another on their proprietary encapsulation technology, C-Stem™ –
BORDEAUX, FRANCE, May 29th 2024 – TreeFrog Therapeutics has a busy schedule at the ISCT’s 30th annual meeting, taking place in Vancouver, Canada this week, with two posters being presented, one of which has been awarded the Best Poster in the iPSC category. A poster on their transformational encapsulation technology, C-Stem™, will also be presented.
TreeFrog is a cell therapy company with a lead program in Parkinson’s disease, a complex neurodegenerative disease with no cure and treatments that offer symptomatic relief only. Decades of research demonstrate that cell therapy holds immense promise for Parkinson’s disease, with multiple clinical trials ongoing. However, the manufacturing of these cells must overcome major pharmaceutical challenges, including scalability, to be compatible with potential commercial phases. The cell therapy program at TreeFrog is based on C-Stem™, a proprietary technology platform that overcomes these challenges. In 2021, the company achieved a world-first of producing 15 billion iPSCs in one run, in one week.
Michaël Lanero Fidalgo, Chief Operating Officer, will represent the company for the Best Poster in the iPSC category, an award designed to recognize outstanding abstracts related to iPSC research. Poster #1219, First Off-The-Shelf Bioreactor Produced, iPSC-Derived Neural Microtissues Containing Dopaminergic Neurons Innervate the Striatum and Normalize Behavior in a Parkinson Rat Model, is also one of only twenty posters chosen for an elevator pitch presentation from the overall 600 considered.
Kévin Alessandri, co-founder and Chief Technology Officer, will present poster #1200 Cell encapsulation as a tool for stem cell-based cell therapy industrialization, a deep dive into how the C-Stem™ technology, can overcome the bottlenecks of the complex Chemistry, Manufacturing and Controls (CMC) in cell therapy. He will also participate as a KOL in the JSRM-ISCT iPSC workshop event iPSCs: From Bench to Bedside’ Scientific Signature Series.
Events:
- Elevator Pitch presentation by Michael Lanero-Fidalgo, representing lead authors Nicolas Prudon & Lucia Cordero Espinoza
Details: Wednesday May 29th, 2024 @ 12:00 – 13:00, Room 201 - iPSC Poster Presentation Networking reception (Posters #1219 & #1200)
Details: Thursday May 30th @ 18:00 – 19:30 Exhibit & Poster Hall - iPSC: Bench to Bedside: Scientific Signature Series, participation of Kevin Alessandri as KOL.
Details: Saturday June 1st, 2024 @ 7:30 – 16:00 Room 212-214
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry — producing and differentiating cells of quality at unprecedented scale, cost-effectively. To realize their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players in other areas. In the last 3 years, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. In 2022, the company opened technological hubs in Boston, USA, and Kobe, Japan, to drive the adoption of the C-StemTM platform and establish strategic alliances with leading academic, biotech and industry players.
Media Contacts
Rachel MOONEY,
Chief Communications Officer
rachel.mooney@treefrog.fr
+33 6 74 06 34 61